Best Practices in the Treatment and Management of Acute Myeloid Leukemia (AML): Managed Care Decision Making in an Evolving Landscape

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2023 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2023 to August 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AbbVie, Jazz Pharmaceuticals, and Servier Pharmaceuticals LLC

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. The American Cancer Society estimates that there were approximately 20,050 new cases of AML and 11,540 deaths from AML in the United States in 2022. The five-year survival rate has not improved in older patients despite 40 years of research. Fortunately for patients with AML, many new treatments are now here. New options, which have the ability to target certain types of mutations, have been approved in AML for the first time since 1990. With so many new options becoming available in the past few years, the treatment paradigm in AML, especially in relapsed or refractory and high-risk disease and in maintenance settings, has drastically changed. With that change comes a knowledge gap among physician medical directors, oncologists, practicing physicians and nurses. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm, which will ultimately improve patient outcomes in the AML patient population.

Upon completion of this activity, participants will be able to:

  • Assess the clinical and economic burden of AML, including factors that contribute to poor prognosis and increased costs

  • Outline the role of molecular alterations and cytogenetic testing for risk stratification and treatment planning in AML

  • Analyze recent data on the efficacy and safety of novel therapeutics in AML, including newer targeted, cytotoxic, and antibody-based strategies, in a range of patient populations

  • Summarize clinical, molecular/genetic, and pathologic features of secondary AML and cite efficacy and safety evidence surrounding the use of novel therapeutics in these patients

  • Explore the evolving role of oral IDH1 inhibitors in patients with AML with an IDH1 mutation, including newer combination options

  • Employ interventions such as clinical pathways and site of care initiatives for optimal cost management and improved outcomes in AML, including secondary AML


Faculty: Jeffrey E. Lancet, MD
Chair, Dept of Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Lancet has served as a consultant for AbbVie, Bristol Myers Squibb, Jasper Therapeutics, Jazz Pharmaceuticals, Novartis, and Servier. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AbbVie, Jazz Pharmaceuticals, and Servier Pharmaceuticals LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue